Research  >  Research centres  >  Harquail Centre for Neuromodulation  >  Clinical trials  >  Psychiatry trials
Share:  
|
PAGE
MENU

Psychiatry trials

MR-guided Focused Ultrasound (MRgFUS) Bilateral Capsulotomy for the Treatment of Refractory Obsessive-Compulsive Disorder (OCD)

A large proportion of patients with Obsessive Compulsive Disorder (OCD) continue to have symptoms despite various medical and psychiatric treatments.

MR-guided Focused Ultrasound thermal ablation offers the possibility of reaching and treating an area deep in the brain, called the anterior limb of the internal capsule (ALIC) by creating lesions to precisely targeted regions. This does not require open surgical approaches and lesions are generated in real-time under MR image guidance.

The proposed study is to evaluate the safety and efficacy of focused ultrasound for patients with treatment-resistant OCD. Assessments for any adverse events, clinical symptom relief, and quality of life will be made before and after the focused ultrasound treatment.

Ten patients, aged 20-80, will undergo one round of focused ultrasound, and then be assessed for severity of depression and level of functioning up to 12 months following treatment.

For more information or to inquire about eligibility for the trial, please email harquailcentre@sunnybrook.ca. Please indicate in the subject line your diagnosis and which study you are inquiring about.

MR-guided Focused Ultrasound (MRgFUS) Bilateral Capsulotomy for the Treatment of Refractory Major Depression

In this North American first study, researchers are investigating the safety and effectiveness of focused ultrasound to help patients with treatment-resistant Major Depression.. About 10% of people with recurrent major depression, will have treatment resistant Major Depression making them at risk for continued morbidity, and in some cases mortality. In Ontario this represents around 190,000 people.

This study is evaluating the safety and efficacy of MRgFUS for patients with treatment-resistant Major Depression and will target and lesion the anterior limb of the internal capsule (ALIC).Assessments for any adverse events, clinical symptom relief, and quality of life will be made before and after the focused ultrasound treatment.

In this trial, six patients, aged 25-80 years, will undergo one round of focused ultrasound, and then be assessed for severity of depression and level of functioning up to 12 months following their treatment.

For more information or to inquire about eligibility for the trial, please email harquailcentre@sunnybrook.ca. Please indicate in the subject line your diagnosis and which study you are inquiring about.

Deep Brain Stimulation (DBS) for the Treatment of Refractory Post-Traumatic Stress Disorder (PTSD): Pilot Trial

The purpose of this study is to determine the safety and feasibility of DBS in people with Post-traumatic Stress Disorder (PTSD). Research shows there are similarities between the symptoms of PTSD and those of anxiety and depression and DBS has shown promise in the treatment of those conditions.

In this trial five patients, aged 18-70 years will undergo a DBS implant. The length of this study from the time of enrollment, is approximately 14 months.

For more information or to inquire about eligibility for the trial, please email harquailcentre@sunnybrook.ca. Please indicate in the subject line your diagnosis and which study you are inquiring about.

Deep Brain Stimulation (DBS) for the Treatment of Refractory Alcohol Use Disorder (AUD): Pilot Trial

Treatment refractory alcohol use disorder (AUD) is a chronic and debilitating disease associated with high morbidity. Despite advances in neuroimaging, genetics, pharmacology and psychosocial interventions,, little progress has been made in altering the natural history of the condition or its outcome.

This study will investigate surgical therapy for the treatment of refractory alcoholism. It will focus on a part of the brain known as the core of the nucleus accumbens, which plays a role in addiction. It is also an area known to be successful in managing alcohol cravings and in helping maintain abstinence.

Five subjects will be enrolled in this open label trial for the one year.. The primary objective of the trial is to investigate the safety and efficacy of DBS in patients with treatment refractory AUD. This will be determined by various outcome measures that will include validated scales to assess addiction and craving behaviours.

Assessment of Safety and Feasibility of Exablate Neuro system to perform Echo-Focusing Echo Imaging in Patients with Treatment-Resistant Neurologic and Psychiatric Indications

Magnetic resonance-guided focused ultrasound (MRgFUS) can be used to perform ablative neurosurgical procedures, mitigating the risks of open cranial approaches. To date, MRgFUS approved, for the treatment of patients with refractory essential tremor, and there is a growing experience in refractory psychiatric illnesses. The ability to generate a lesion, depends primarily on the patient’s skull density. In this study, we use a new technique called Echo-focusing to enhance efficiency of ultrasound transmission through the skull and be able to treat those who would otherwise be ineligible for a lesioning procedure.

The objective of the proposed study is to evaluate the safety and effectiveness of Echo-Focusing using Exablate Neuro as a tool for treating patients with treatment-refractory neurologic and psychiatric disorders: refractory essential tremor, major depressive disorder (MDD), obsessive compulsive disorder (OCD), post-traumatic stress disorder (PTSD) (with comorbid MDD or OCD), and anorexia nervosa (with comorbid MDD or OCD). We believe that this will be safer than and as effective as open neurosurgery, while mitigating the risks of open cranial approaches.

A total of 46 subjects will be enrolled. Safety will be determined by an evaluation of the incidence and severity of procedure-related complications from the treatment day visit through the 12-month post–treatment time point.

For more information or to inquire about eligibility for the trial, please email harquailcentre@sunnybrook.ca. Please indicate in the subject line your diagnosis and which study you are inquiring about.